1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Marvel Biosciences Corp

Marvel Biosciences Corp

0.12
CAD
+0.00
(-4.17%)
-0.02EPS
10.71MMarket Cap
Marvel Biosciences Corp
TSXV:MRVL
(TSX Venture Exchange)

Recent

price

0.12

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
TTM
CAD
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.17
-0.08
-0.06
-0.04
-0.05
-0.02
Basic EPS, GAAP
-0.02
-0.08
-0.07
-0.03
-0.03
-0.02
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.07
0.01
-0.04
-0.06
-0.08
-0.04
Book Value per Share
- -
0.07
0.01
-0.04
-0.06
-0.08
-0.04
Tangible Book Value per Share
33
18
33
40
40
47
57
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-3
-3
-2
-2
-2
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
2
- -
-1
-3
-4
-2
Working Capital
- -
- -
- -
1
2
- -
1
LT Debt
- -
2
- -
-2
-3
-4
-3
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-245.66
-200.23
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
2
2
1
LT Borrowings
- -
- -
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
63
Market Capitalization
13
8
11

Working Capital

CAD

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
3
Payables & Accruals
2
2
2
ST Debt
2
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
183.5%
41.77%
Free Cash Flow
- -
32.27%
-2.47%
Net Income, GAAP
- -
39.56%
34.02%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
-0.01
-0.01
-0.01
-0.04
2025
-0.01
-0.01
-0.01
-0.02
-0.05
2026
-0.01
-0.01
0.01
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Marvel Biosciences Corp. Marvel Biosciences Corp. (TSXV: MRVL), a Calgary, Alberta-based pre-clinical stage biotechnology company founded in 2021, develops synthetic chemical derivatives of off-patent drugs targeting the A2A adenosine receptor for neurological and non-neurological diseases; its lead product candidate, MB-204, a novel fluorinated derivative of Istradefylline originally approved for Parkinson's disease, demonstrates preclinical efficacy in Alzheimer's disease, depression, anxiety, autism, attention deficit hyperactivity disorder, Rett syndrome, Fragile X syndrome, and non-alcoholic steatohepatitis-associated liver fibrosis; additional pipeline assets include other A2A receptor inhibitors for cancer and related indications, supported by its wholly owned subsidiary Marvel Biotechnology Inc. The company operates primarily in Canada with global patent pursuits and targets large unmet needs in neurological diseases, cognitive and behavioral health, and neurodevelopmental genetic disorders through a drug redevelopment platform that reduces development costs, timelines, and risks compared to traditional biotech models. Recent developments include closing multiple tranches of non-brokered private placements raising up to $2.5 million in early 2025 for advancement toward Phase 1 clinical trials following completion of cGMP synthesis and toxicology studies; receipt of a notice of allowance for a composition-of-matter patent on MB-204 in China in January 2025, the first worldwide for this compound family; promising preclinical data from Rett syndrome studies in collaboration with the iBraiN Institute showing MB-204 outperforming trofinetide, prompting plans to file for U.S. FDA Orphan Drug Designation in March 2025; and selections for oral presentations at the 2025 IRSF Rett Syndrome Scientific Meeting and Alzheimer's Association International Conference.

Company News

Company News APIChatGPT

  • feeds.newsfilecorp.com

    Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars

  • feeds.newsfilecorp.com

    Marvel Biosciences annonce la prolongation de la date limite de clôture du placement privé

  • feeds.newsfilecorp.com

    Marvel Biosciences Announces Grant of Deferred Share Units

  • defenseworld.net

    Marvell Technology (NASDAQ:MRVL) Shares Up 2.1% After Analyst Upgrade

  • defenseworld.net

    Hager Investment Management Services LLC Has $1.53 Million Holdings in Marvell Technology, Inc. $MRVL

  • defenseworld.net

    Chris Koopmans Sells 10,000 Shares of Marvell Technology (NASDAQ:MRVL) Stock

  • defenseworld.net

    Mark Casper Sells 6,900 Shares of Marvell Technology (NASDAQ:MRVL) Stock

  • feeds.newsfilecorp.com

    Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders

  • feeds.newsfilecorp.com

    Bourse de Toronto, Marvel Biosciences Corp., Perspective de la haute direction